Who are ICI35,868 (Diprivan)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zulresso, Onfi, Lusedra, Campral, Sonata, Suprane.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ici35-868-diprivan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

ICI35,868 (Diprivan) — Competitive Intelligence Brief

ICI35,868 (Diprivan) (ICI35,868 (Diprivan)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Intravenous sedative-hypnotic. Area: Anesthesia.

phase 3 Intravenous sedative-hypnotic GABA-A receptor Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

ICI35,868 (Diprivan) (ICI35,868 (Diprivan)) — AstraZeneca. Propofol is a rapid-acting intravenous sedative-hypnotic agent that enhances inhibitory GABAergic neurotransmission in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ICI35,868 (Diprivan) TARGET	ICI35,868 (Diprivan)	AstraZeneca	phase 3	Intravenous sedative-hypnotic	GABA-A receptor
Zulresso	BREXANOLONE	Sage Therap	marketed	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator	GABA-A receptor alpha-1/beta-2/gamma-2	2019-01-01
Onfi	CLOBAZAM	Lundbeck Pharms Llc	marketed	Benzodiazepine [EPC]	GABA-A receptor alpha-1/beta-2/gamma-2	2011-01-01
Lusedra	FOSPROPOFOL		marketed	fospropofol	GABA-A receptor	2008-01-01
Campral	ACAMPROSATE	Allergan/AbbVie	marketed	acamprosate	GABA-A receptor alpha-1/beta-3/gamma-2	2004-01-01
Sonata	ZALEPLON	Pfizer	marketed	gamma-Aminobutyric Acid A Receptor Agonist [EPC]	GABA-A receptor alpha-1/beta-2/gamma-2	1999-01-01
Suprane	DESFLURANE	Baxter	marketed	General Anesthetic [EPC]	GABA-A receptor; anion channel	1992-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2039-09-05 — Onfi · 12403090 · Formulation · US
2039-09-05 — Onfi · 12290597 · Formulation · US
2040-01-31 — Onfi · 11541002 · Formulation · US

Sponsor landscape (Intravenous sedative-hypnotic class)

AstraZeneca · 1 drug in this class
Brugmann University Hospital · 1 drug in this class
Centre Hospitalier Universitaire Dijon · 1 drug in this class
Fayoum University Hospital · 1 drug in this class
Iuliu Hatieganu University of Medicine and Pharmacy · 1 drug in this class
RenJi Hospital · 1 drug in this class
Second Affiliated Hospital, School of Medicine, Zhejiang University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ICI35,868 (Diprivan) — Competitive Intelligence Brief. https://druglandscape.com/ci/ici35-868-diprivan. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab